Site icon BioInformant

How to Create Strategically Positioned Stem Cell Product Lines

BioInformant Supports Strategically Positioned Stem Cell Product Lines

BioInformant, a specialized market research firm serving the life science industry, announces the release of its latest report, “Stem Cell Research Products: Opportunities, Tools & Technologies.” The report combines technology-derived market data with end-user survey findings, exploring current market conditions and providing guidance to companies looking to develop strategically positioned stem cell product lines.

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including: embryonic, perinatal, adult, and cancer stem cells. Of interest to researchers is the potential for the use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders. Also, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to pharmaceutical companies.

To facilitate this research, a vast stem cell research products market is emerging. Large companies selling stem cell research products include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Lonza, Clontech (a Takara Bio Company), and GE Healthcare Life Sciences. Products offered by these companies include: antibodies to stem cell antigens, bead-based stem cell separation systems, stem cell protein purification and analysis tools, tools for DNA and RNA-based characterization of stem cells, stem cell culture and media reagents, stem cell specific growth factors and cytokines, tools for stem cell gene regulation, a range of stem cell services, tools for in vivo and in vitro stem cell tracking, and stem cell lines.

“A more in-depth understanding of the needs of scientists studying stem cells is of growing importance as the field becomes more complex and funding sources become harder to obtain,” explained Cade Hildreth, President/CEO of BioInformant.com.

This market report includes:

Released February 2016, “Stem Cell Research Products: Opportunities, Tools & Technologies ” explores current market conditions within the stem cell research products market, provides strategic guidance for competing within the industry, and quantifies important trends, metrics, and findings to guide the decision-making of competitors across the stem cell research products marketplace.

Click here to view the full Executive Summary and Table of contents for the report: https://bioinformant.wpengine.com/product/stem-cell-research-products-opportunities-tools-and-technologies/.


Want to be better informed than your competition? Get future stem cell industry updates.

 

About Us

BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.

Click here to view our global strategic reports for the stem cell and cord blood industry.

Rate this post
Exit mobile version